Figures & data
Table 1 Risk segments and collapsed risk cohorts used in this analysis
Table 2 Patient demographics and clinical characteristics
Figure 1 Physician responses to the question “To what extent are you aware of the 2012 ADA Position Statement?”.
![Figure 1 Physician responses to the question “To what extent are you aware of the 2012 ADA Position Statement?”.](/cms/asset/bf195cdf-32ff-41cf-bb58-e0bdf58c22aa/drmh_a_116800_f0001_b.jpg)
Figure 2 Physician responses to the question “How did you learn about the 2012 ADA Position Statement?” (multiple options could be selected).
![Figure 2 Physician responses to the question “How did you learn about the 2012 ADA Position Statement?” (multiple options could be selected).](/cms/asset/cf3eb2cf-8055-41bb-802a-defbf44afbcd/drmh_a_116800_f0002_b.jpg)
Figure 3 Physician responses to the question “Do you believe the new ADA Position Statement will impact how you set target A1C levels for other T2D patients in your practice?”.
![Figure 3 Physician responses to the question “Do you believe the new ADA Position Statement will impact how you set target A1C levels for other T2D patients in your practice?”.](/cms/asset/300f8b31-526a-4036-80e4-f2b185b3b15e/drmh_a_116800_f0003_b.jpg)
Figure 4 Impact of educational intervention on physician target A1C setting, by risk segment.a
Abbreviation: A1C, glycated hemoglobin.
![Figure 4 Impact of educational intervention on physician target A1C setting, by risk segment.a](/cms/asset/34f4da8c-7eb2-4e29-ab49-adb6b1fefdc9/drmh_a_116800_f0004_b.jpg)
Figure 5 Physician-reported A1C target setting compared with ADA 2012 Position Statement recommendations, by collapsed risk cohort.
Abbreviations: A1C, glycated hemoglobin; ADA, American Diabetes Association; N/A, not available.
![Figure 5 Physician-reported A1C target setting compared with ADA 2012 Position Statement recommendations, by collapsed risk cohort.](/cms/asset/257f64d3-5f8a-45be-90ae-578543ff3d9d/drmh_a_116800_f0005_b.jpg)